Viktor Grünwald

19.7k total citations · 5 hit papers
328 papers, 10.4k citations indexed

About

Viktor Grünwald is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Viktor Grünwald has authored 328 papers receiving a total of 10.4k indexed citations (citations by other indexed papers that have themselves been cited), including 257 papers in Pulmonary and Respiratory Medicine, 145 papers in Oncology and 129 papers in Molecular Biology. Recurrent topics in Viktor Grünwald's work include Renal cell carcinoma treatment (189 papers), Renal and related cancers (98 papers) and Cancer Genomics and Diagnostics (83 papers). Viktor Grünwald is often cited by papers focused on Renal cell carcinoma treatment (189 papers), Renal and related cancers (98 papers) and Cancer Genomics and Diagnostics (83 papers). Viktor Grünwald collaborates with scholars based in Germany, United States and France. Viktor Grünwald's co-authors include Camillo Porta, Bernard Escudier, Manuel Hidalgo, Robert J. Motzer, Thomas E. Hutson, Alain Ravaud, Sergio Bracarda, Robert A. Figlin, Stéphane Oudard and John A. Thompson and has published in prestigious journals such as Proceedings of the National Academy of Sciences, The Lancet and Journal of Clinical Oncology.

In The Last Decade

Viktor Grünwald

298 papers receiving 10.3k citations

Hit Papers

Efficacy of everolimus in... 2008 2026 2014 2020 2008 2010 2019 2024 2023 500 1000 1.5k 2.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial
    2008 2.3k citations Robert J. Motzer, Bernard Escudier et al. The Lancet profile →
  2. Phase 3 trial of everolimus for metastatic renal cell carcinoma
    2010 903 citations Robert J. Motzer, Bernard Escudier et al. profile →
  3. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
    2019 774 citations Bernard Escudier, Camillo Porta et al. profile →
  4. Renal cell carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
    2024 96 citations Laurence Albigès, Axel Bex et al. profile →
  5. Metastatic Prostate Cancer—A Review of Current Treatment Options and Promising New Approaches
    2023 80 citations Ken Herrmann, Boris Hadaschik et al. profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Viktor Grünwald 6.8k 5.5k 4.1k 3.0k 1.1k 328 10.4k
Gary R. Hudes 6.8k 1.0× 6.1k 1.1× 3.5k 0.9× 3.6k 1.2× 1.2k 1.1× 102 10.7k
Sindy T. Kim 8.4k 1.2× 5.9k 1.1× 4.6k 1.1× 3.9k 1.3× 774 0.7× 22 10.9k
Sergio Bracarda 7.6k 1.1× 5.8k 1.0× 4.4k 1.1× 3.8k 1.3× 2.1k 1.9× 236 11.6k
Charles M. Baum 8.2k 1.2× 5.9k 1.1× 4.7k 1.2× 3.4k 1.1× 1.4k 1.3× 71 12.8k
Frédéric Rolland 6.7k 1.0× 4.8k 0.9× 4.3k 1.1× 3.0k 1.0× 2.7k 2.5× 142 11.6k
Xin Huang 7.1k 1.0× 2.8k 0.5× 5.4k 1.3× 2.8k 0.9× 923 0.9× 98 10.2k
Laurence Albigès 10.7k 1.6× 6.5k 1.2× 5.1k 1.3× 4.2k 1.4× 2.1k 2.0× 460 14.4k
Brian Schwartz 5.8k 0.9× 7.7k 1.4× 5.2k 1.3× 3.3k 1.1× 1.3k 1.2× 143 14.4k
I. Bodrogi 6.4k 1.0× 4.3k 0.8× 3.6k 0.9× 2.9k 1.0× 2.4k 2.2× 78 10.3k
Christine Chevreau 10.2k 1.5× 6.3k 1.1× 6.2k 1.5× 3.8k 1.3× 2.7k 2.5× 310 15.6k

Countries citing papers authored by Viktor Grünwald

Since Specialization
Citations

This map shows the geographic impact of Viktor Grünwald's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Viktor Grünwald with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Viktor Grünwald more than expected).

Fields of papers citing papers by Viktor Grünwald

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Viktor Grünwald. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Viktor Grünwald. The network helps show where Viktor Grünwald may publish in the future.

Co-authorship network of co-authors of Viktor Grünwald

This figure shows the co-authorship network connecting the top 25 collaborators of Viktor Grünwald. A scholar is included among the top collaborators of Viktor Grünwald based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Viktor Grünwald. Viktor Grünwald is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Grünwald, Viktor, Axel Bex, Sylvie Rottey, et al.. (2025). Current status of adjuvant immunotherapy and relapse management in renal cell carcinoma: Insights from a European delphi study. European Journal of Cancer. 225. 115569–115569. 1 indexed citations
2.
Szabados, Bernadett, Félix Guerrero‐Ramos, Enrique Grande, et al.. (2025). On the Horizon: A Global Multidisciplinary Perspective on Delivering Emerging Therapies for Patients with BCG-Naïve High-Risk NMIBC. Oncology and Therapy. 13(2). 275–291.
3.
Pabst, Kim M., Viktor Grünwald, Kuangyu Shi, et al.. (2025). Prognostic value of [18F]FDG- and PSMA-PET in patients evaluated for [177Lu]Lu-PSMA therapy of mCRPC. European Journal of Nuclear Medicine and Molecular Imaging. 52(9). 3199–3210. 1 indexed citations
4.
Wei, Weijun, et al.. (2025). CD70-targeted cancer theranostics: Progress and challenges. Med. 6(8). 100671–100671. 4 indexed citations
5.
Eckstein, Markus, Manuel Ritter, Peter Brossart, et al.. (2024). The modified Glasgow Prognostic Score (mGPS) can guide decisions for immunotherapy treatment beyond progression. European Journal of Cancer. 215. 115163–115163. 3 indexed citations
6.
Uhlig, Johannes, Annemarie Uhlig, Hari A. Deshpande, et al.. (2024). Epidemiology, treatment and outcomes of primary renal sarcomas in adult patients. Scientific Reports. 14(1). 10038–10038.
7.
Watanabe, Masao, Wolfgang P. Fendler, Hong Grafe, et al.. (2024). Prognostic Implications of68Ga-FAPI-46 PET/CT–Derived Parameters on Overall Survival in Various Types of Solid Tumors. Journal of Nuclear Medicine. 65(7). 1027–1034. 9 indexed citations
8.
Sweis, Randy F., Pablo Gajate, Rafael Morales‐Barrera, et al.. (2024). Rogaratinib Plus Atezolizumab in Cisplatin-Ineligible Patients With FGFR RNA-Overexpressing Urothelial Cancer. JAMA Oncology. 10(11). 1565–1565. 6 indexed citations
9.
Ralser, Damian J., Marieta Toma, Glen Kristiansen, et al.. (2024). Preclinical evidence for the use of anti‐Trop‐2 antibody‐drug conjugate Sacituzumab govitecan in cerebral metastasized castration‐resistant prostate cancer. Cancer Medicine. 13(12). e7320–e7320. 3 indexed citations
10.
Motzer, Robert J., Camillo Porta, Masatoshi Eto, et al.. (2024). Biomarker analyses in patients with advanced renal cell carcinoma (aRCC) from the phase 3 CLEAR trial.. Journal of Clinical Oncology. 42(16_suppl). 4504–4504. 7 indexed citations
11.
Grünwald, Viktor, Jürgen Becker, Ralf Gutzmer, et al.. (2024). PTHrP-induced hypercalcemic psychosyndrome under combined anti-PD-L1 and anti-EGFR inhibition in penile squamous cell carcinoma – A case report. SHILAP Revista de lepidopterología. 2. 100261–100261. 1 indexed citations
12.
Grünwald, Viktor, Tobias Bald, Manuel Ritter, et al.. (2023). On-treatment Modified Glasgow Prognostic Score Provides Predictive Information Complementary to Radiological Staging in Metastatic Urothelial Carcinoma on Immunotherapy. European Urology Oncology. 7(3). 328–331. 7 indexed citations
13.
14.
15.
Grassi, Paolo, Ludovic Doucet, Viktor Grünwald, et al.. (2017). Outcome of Patients with Renal Cell Carcinoma and Multiple Glandular Metastases Treated with Targeted Agents. Oncology. 92(5). 269–275. 3 indexed citations
16.
Schöffski, Patrick, Agnieszka Woźniak, Bernard Escudier, et al.. (2017). Crizotinib achieves long-lasting disease control in advanced papillary renal-cell carcinoma type 1 patients with MET mutations or amplification. EORTC 90101 CREATE trial. European Journal of Cancer. 87. 147–163. 94 indexed citations
17.
Schmitt, Thomas, Regine Mayer‐Steinacker, Frank Mayer, et al.. (2016). Vorinostat in refractory soft tissue sarcomas – Results of a multi-centre phase II trial of the German Soft Tissue Sarcoma and Bone Tumour Working Group (AIO). European Journal of Cancer. 64. 74–82. 32 indexed citations
18.
Escudier, Bernard, Viktor Grünwald, Alain Ravaud, et al.. (2014). Phase II Results of Dovitinib (TKI258) in Patients with Metastatic Renal Cell Cancer. Clinical Cancer Research. 20(11). 3012–3022. 49 indexed citations
19.
Motzer, Robert J., Bernard Escudier, Stéphane Oudard, et al.. (2008). Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. The Lancet. 372(9637). 449–456. 2339 indexed citations breakdown →
20.
Garrett-Engele, Carrie M., Uta Kossatz-Boehlert, Xueyan Chen, et al.. (2006). Testing the importance of p27 degradation by the SCF skp2 pathway in murine models of lung and colon cancer. Proceedings of the National Academy of Sciences. 103(38). 14009–14014. 60 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Gary R. Hudes Breakdown of academic impact, for papers by Sindy T. Kim Breakdown of academic impact, for papers by Sergio Bracarda Breakdown of academic impact, for papers by Charles M. Baum Breakdown of academic impact, for papers by Frédéric Rolland Breakdown of academic impact, for papers by Xin Huang Breakdown of academic impact, for papers by Laurence Albigès Breakdown of academic impact, for papers by Brian Schwartz Breakdown of academic impact, for papers by I. Bodrogi Breakdown of academic impact, for papers by Christine Chevreau
Rankless by CCL
2026